TABLE OF CONTENTS
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Retinal Vein Occlusion Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
4 Type Overview
4.1 Introduction
4.1.1 Market Size & Forecast
4.2 Branch Retinal Artery Occlusion
4.3 Central Retinal Vein Occlusion
5 Condition Overview
5.1 Introduction
5.1.1 Market Size & Forecast
5.2 Non-Ischemic
5.3 Ischemic
6 Diagnosis Overview
6.1 Introduction
6.1.1 Market Size & Forecast
6.2 Optical coherence tomography (OCT)
6.3 Fundoscopic examination
6.4 Fluorescein angiography
6.5 Others
7 Treatment Overview
7.1 Introduction
7.1.1 Market Size & Forecast
7.2 Anti-vascular endothelial growth factor
7.3 Corticosteroid drugs
7.4 Laser retinal photocoagulation
7.5 Others
8 End User Overview
8.1 Introduction
8.1.1 Market Size & Forecast
8.2 Hospitals and clinics
8.3 Research & academics centers
8.4 Others
9 Regional Overview
9.1 Introduction
9.1.1 Market Size & Forecast
9.2 America
9.2.1 North America
9.2.1.1 U.S.
9.2.1.1.1 By Type
9.2.1.1.2 By Condition
9.2.1.1.3 By Diagnosis
9.2.1.1.4 By Treatment
9.2.1.1.5 By End User
9.2.1.2 Canada
9.2.1.2.1 By Type
9.2.1.2.2 By Condition
9.2.1.2.3 By Diagnosis
9.2.1.2.4 By Treatment
9.2.1.2.5 By End User
9.2.1.3 Mexico
9.2.1.3.1 By Type
9.2.1.3.2 By Condition
9.2.1.3.3 By Diagnosis
9.2.1.3.4 By Treatment
9.2.1.3.5 By End User
9.2.2 South America
9.2.2.1 By Type
9.2.2.2 By Condition
9.2.2.3 By Diagnosis
9.2.2.4 By Treatment
9.2.2.5 By End User
9.3 Europe
9.3.1 Market Size & Forecast (Value)
9.3.2 Western Europe
9.3.2.1 Germany
9.3.2.1.1 By Type
9.3.2.1.2 By Condition
9.3.2.1.3 By Diagnosis
9.3.2.1.4 By Treatment
9.3.2.1.5 By End User
9.3.2.2 France
9.3.2.2.1 By Type
9.3.2.2.2 By Condition
9.3.2.2.3 By Diagnosis
9.3.2.2.4 By Treatment
9.3.2.2.5 By End User
9.3.2.3 U.K.
9.3.2.3.1 By Type
9.3.2.3.2 By Condition
9.3.2.3.3 By Diagnosis
9.3.2.3.4 By Treatment
9.3.2.3.5 By End User
9.3.2.4 Italy
9.3.2.4.1 By Type
9.3.2.4.2 By Condition
9.3.2.4.3 By Diagnosis
9.3.2.4.4 By Treatment
9.3.2.4.5 By End User
9.3.2.5 Spain
9.3.2.5.1 By Type
9.3.2.5.2 By Condition
9.3.2.5.3 By Diagnosis
9.3.2.5.4 By Treatment
9.3.2.5.5 By End User
9.3.2.6 Rest of Western Europe
9.3.2.6.1 By Type
9.3.2.6.2 By Condition
9.3.2.6.3 By Diagnosis
9.3.2.6.4 By Treatment
9.3.2.6.5 By End User
9.3.3 Eastern Europe
9.4 Asia Pacific
9.4.1 Market Size & Forecast (Value)
9.4.2 China
9.4.2.1 By Type
9.4.2.2 By Condition
9.4.2.3 By Diagnosis
9.4.2.4 By Treatment
9.4.2.5 By End User
9.4.3 India
9.4.3.1 By Type
9.4.3.2 By Condition
9.4.3.3 By Diagnosis
9.4.3.4 By Treatment
9.4.3.5 By End User
9.4.4 Japan
9.4.4.1 By Type
9.4.4.2 By Condition
9.4.4.3 By Diagnosis
9.4.4.4 By Treatment
9.4.4.5 By End User
9.4.5 South Korea
9.4.5.1 By Type
9.4.5.2 By Condition
9.4.5.3 By Diagnosis
9.4.5.4 By Treatment
9.4.5.5 By End User
9.4.6 Australia
9.4.6.1 By Type
9.4.6.2 By Condition
9.4.6.3 By Diagnosis
9.4.6.4 By Treatment
9.4.6.5 By End User
9.4.7 Rest of Asia-Pacific
9.4.7.1 By Type
9.4.7.2 By Condition
9.4.7.3 By Diagnosis
9.4.7.4 By Treatment
9.4.7.5 By End User
9.5 Middle East & Africa
9.5.1 Market Size & Forecast (Value)
9.5.2 The Middle East
9.5.2.1 South Africa
9.5.2.1.1 By Type
9.5.2.1.2 By Condition
9.5.2.1.3 By Diagnosis
9.5.2.1.4 By Treatment
9.5.2.1.5 By End User
9.5.2.2 UAE
9.5.2.2.1 By Type
9.5.2.2.2 By Condition
9.5.2.2.3 By Diagnosis
9.5.2.2.4 By Treatment
9.5.2.2.5 By End User
9.5.2.3 Qatar
9.5.2.3.1 By Type
9.5.2.3.2 By Condition
9.5.2.3.3 By Diagnosis
9.5.2.3.4 By Treatment
9.5.2.3.5 By End User
9.5.2.4 Rest of Middle East
9.5.2.4.1 By Type
9.5.2.4 2 By Condition
9.5.2.4 3 By Diagnosis
9.5.2.4 4 By Treatment
9.5.2.4 5 By End User
9.5.3 Africa
9.5.3.1 By Type
9.5.3.2 By Condition
9.5.3.3 By Diagnosis
9.5.3.4 By Treatment
9.5.3.5 By End User
10. Company Profile
10.1 ALLERGAN
10.1.1 Company Overview
10.1.2 Financial Performance
10.1.3 Recent Developments
10.1.4 Product Portfolio
10.2 Bayer AG
10.2.1 Company Overview
10.2.2 Financial Performance
10.2.3 Recent Developments
10.2.4 Product Portfolio
10.3 Bristol-Myers Squibb Company
10.3.1 Company Overview
10.3.2 Financial Performance
10.3.3 Recent Developments
10.3.4 Product Portfolio
10.4 Regeneron
10.4.1 Company Overview
10.4.2 Financial Performance
10.4.3 Recent Developments
10.4.4 Product Portfolio
10.5 Ellex
10.5.1 Company Overview
10.5.2 Financial Performance
10.5.3 Recent Developments
10.5.4 Product Portfolio
10.6 Novartis AG
10.6.1 Company Overview
10.6.2 Financial Performance
10.6.3 Recent Developments
10.6.4 Product Portfolio
10.7 F. Hoffmann-La Roche Ltd
10.7.1 Company Overview
10.7.2 Financial Performance
10.7.3 Recent Developments
10.7.4 Product Portfolio
10.8 Topcon Corporation
10.8.1 Company Overview
10.8.2 Financial Performance
10.8.3 Recent Developments
10.8.4 Product Portfolio
10.9 IRIDEX Corporation
10.9.1 Company Overview
10.9.2 Financial Performance
10.9.3 Recent Developments
10.9.4 Product Portfolio
10.10 Sanofi
10.10.1 Company Overview
10.10.2 Financial Performance
10.10.3 Recent Developments
10.10.4 Product Portfolio
